{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:11:59Z","timestamp":1790187119343,"version":"4.1.0"},"reference-count":108,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this article is to update evidence on the efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) and provide information to the taskforce for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis (RA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched various databases for randomised controlled trials on RA published until June 2022, with no language restriction. For each of the 15 clinical questions, two independent reviewers screened the articles, evaluated the core outcomes, and performed meta-analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Subcutaneous injection of methotrexate (MTX) showed similar efficacy to oral MTX in MTX-na\u00efve RA patients. Ozoralizumab combined with MTX improved drug efficacy compared to the placebo in RA patients with inadequate response (IR) to conventional synthetic DMARD (csDMARD). Rituximab with and without concomitant csDMARDs showed similar efficacy to other biological DMARDs (bDMARDs) in bDMARD-IR RA patients. Combined Janus kinase inhibitors and MTX achieved similar clinical responses and equal safety during a 4-year period compared to tumour necrosis factor inhibitors in MTX-IR RA patients. Biosimilars showed efficacy equivalent to that of the original bDMARDs in csDMARD-IR and bDMARD-IR RA patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This systematic review provides latest evidence for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for RA management.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae049","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T20:37:20Z","timestamp":1717101440000},"page":"1079-1094","source":"Crossref","is-referenced-by-count":17,"title":["Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8130-4350","authenticated-orcid":false,"given":"Yoichi","family":"Nakayama","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, National Defense Medical College , Tokorozawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Nephrology, Japanese Red Cross Maebashi Hospital , Maebashi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Fukui","sequence":"additional","affiliation":[{"name":"Department of Emergency and General Medicine, Kyorin University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Hosokawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Ueno","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Joint Surgery, Research Hospital, The Institute of Medical Science, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Sumitomo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kobe City Medical Center General Hospital , Kobe,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Tabuchi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Ikeuchi","sequence":"additional","affiliation":[{"name":"Department of Preventive Services, School of Public Health, Graduate School of Medicine and Faculty of Medicine, Kyoto University , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Kawamori","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Sofue","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goro","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kyushu University Beppu Hospital , Oita,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runa","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery and Rheumatology, Otokoyama Hospital , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Hirota","sequence":"additional","affiliation":[{"name":"Department of Infection and Rheumatology, University of Fukui Hospital , Fukui,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Minegishi","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Maeshima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nishida Hospital , Saiki,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Motoyama","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine , Kawasaki,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Preventive Services, School of Public Health, Graduate School of Medicine and Faculty of Medicine, Kyoto University , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma Tsuzuki","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University , Saitama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine of Rheumatic Diseases, Graduate School of Medicine, Kyoto University , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yokohama City University Graduate School of Medicine , Yokohama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yanai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kida","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nishiwaki","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital , Yokohama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yajima","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kawahito","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2603","authenticated-orcid":false,"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"2024110410421799000_R1","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","article-title":"The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study","volume":"73","author":"Cross","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R2","doi-asserted-by":"crossref","DOI":"10.1186\/ar2951","article-title":"Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study","volume":"12","author":"Sokka","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2024110410421799000_R3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R4","first-page":"939","article-title":"Guidelines for the management of rheumatoid arthritis (in Japanese)","volume":"74","author":"Kawahito","year":"2016","journal-title":"Nihon Rinsho"},{"key":"2024110410421799000_R5","volume-title":"Cochrane Handbook for Systematic Reviews of Inter-ventions Version 6.2 (Updated February 2022)","author":"Higgins","year":"2022"},{"key":"2024110410421799000_R6","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2024110410421799000_R7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence\u2014imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2024110410421799000_R8","article-title":"2024 Revision of Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis","author":"Japan College of Rheumatology","year":"2024"},{"key":"2024110410421799000_R9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2024110410421799000_R10","first-page":"483","article-title":"Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis","volume":"22","author":"Islam","year":"2013","journal-title":"Mymensingh Med J"},{"key":"2024110410421799000_R11","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/mr\/roac103","article-title":"Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2024110410421799000_R12","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/art.42273","article-title":"Phase II\/III results of a trial of anti-tumor necrosis factor multivalent NANOBODY compound ozoralizumab in patients with rheumatoid arthritis","volume":"74","author":"Takeuchi","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024110410421799000_R13","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1093\/rheumatology\/keab153","article-title":"Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)","volume":"60","author":"Behrens","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024110410421799000_R14","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"2024110410421799000_R15","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2024110410421799000_R16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/annrheumdis-2014-206015","article-title":"MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study","volume":"75","author":"Peterfy","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R17","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","article-title":"Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab\u2019s Efficacy in MTX iNadequate rEsponders (SERENE))","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R18","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/rheumatology\/kel358","article-title":"Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years","volume":"45","author":"Strand","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"2024110410421799000_R19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(16)00380-9","article-title":"Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial","volume":"388","author":"Porter","year":"2016","journal-title":"Lancet"},{"key":"2024110410421799000_R20","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2024110410421799000_R21","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R22","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0630-5","article-title":"Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial","volume":"17","author":"Manders","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2024110410421799000_R23","first-page":"1","article-title":"Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT","volume":"22","author":"Brown","year":"2018","journal-title":"Health Technol Assess"},{"key":"2024110410421799000_R24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"2024110410421799000_R25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2024110410421799000_R26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"2024110410421799000_R27","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/art.40054","article-title":"Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024110410421799000_R28","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R30","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/14397595.2014.995875","article-title":"Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study","volume":"25","author":"Tanaka","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2024110410421799000_R31","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R32","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R33","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R34","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024110410421799000_R35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.150613","article-title":"Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study","volume":"43","author":"Tanaka","year":"2016","journal-title":"J Rheumatol"},{"key":"2024110410421799000_R36","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2024110410421799000_R37","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","article-title":"A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone","volume":"64","author":"Kremer","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2024110410421799000_R38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2024110410421799000_R39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.39955","article-title":"Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate","volume":"69","author":"Kivitz","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024110410421799000_R40","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"2024110410421799000_R41","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1049-3","article-title":"Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis","volume":"18","author":"Genovese","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024110410421799000_R42","first-page":"732","article-title":"Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study","volume":"38","author":"Li","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2024110410421799000_R43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24\u2005weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R44","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024110410421799000_R45","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"2024110410421799000_R46","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R47","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2024110410421799000_R48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"2024110410421799000_R49","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"2024110410421799000_R50","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy","volume":"68","author":"Kremer","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024110410421799000_R51","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"2024110410421799000_R52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"2024110410421799000_R53","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"key":"2024110410421799000_R54","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","article-title":"A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy","volume":"76","author":"Choe","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R55","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1646-4","article-title":"A randomized controlled trial comparing PF-06438179\/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy","volume":"20","author":"Cohen","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2024110410421799000_R56","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/14397595.2018.1533063","article-title":"A randomized double-blind parallel-group phase III study to compare the efficacy and safety of NI-071 and infliximab reference product in Japanese patients with active rheumatoid arthritis refractory to methotrexate","volume":"29","author":"Matsuno","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2024110410421799000_R57","article-title":"EU Clinical Trials Register: Clinical Trial Results (NCT No. NCT02468791)","author":"European Medicines Agency"},{"key":"2024110410421799000_R58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40744-021-00396-8","article-title":"Fine comparison of the efficacy and safety between GB242 and infliximab in patients with rheumatoid arthritis: a phase III study","volume":"9","author":"Liu","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2024110410421799000_R59","first-page":"1","article-title":"Comparative study for efficacy and safety of biosimilar infliximab in patients with active rheumatoid arthritis on a stable dose of methotrexate","volume":"1","author":"Apsangikar","year":"2018","journal-title":"J Arth Rheumatol Res"},{"key":"2024110410421799000_R60","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/injr.injr_107_17","article-title":"A prospective, randomized, double\u2013blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate","volume":"13","author":"Apsangikar","year":"2018","journal-title":"Indian J Rheumatol"},{"key":"2024110410421799000_R62","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00296-019-04359-9","article-title":"A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study","volume":"39","author":"Lila","year":"2019","journal-title":"Rheumatol Int"},{"key":"2024110410421799000_R63","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-2142-1","article-title":"Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis","volume":"22","author":"Genovese","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2024110410421799000_R64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40744-019-00186-3","article-title":"A comparative study to assess the efficacy, safety, and immunogenicity of YLB113 and the etanercept reference product for the treatment of patients with rheumatoid arthritis","volume":"7","author":"Yamanaka","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2024110410421799000_R65","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/annrheumdis-2015-207588","article-title":"A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy","volume":"76","author":"Emery","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R66","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/annrheumdis-2017-212172","article-title":"Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate","volume":"77","author":"Matsuno","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R67","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2015-207613","article-title":"A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study","volume":"76","author":"Bae","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R68","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000757","article-title":"Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study","volume":"4","author":"Matucci-Cerinic","year":"2018","journal-title":"RMD Open"},{"key":"2024110410421799000_R69","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1097\/RHU.0000000000001616","article-title":"Efficacy, safety, and immunogenicity of biosimilar etanercept (enerceptan) versus its original form in combination with methotrexate in patients with rheumatoid arthritis: a randomized, multicenter, evaluator-blinded, noninferiority study","volume":"27","author":"Strusberg","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"2024110410421799000_R70","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/1756-185X.12711","article-title":"A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis","volume":"19","author":"Jani","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"2024110410421799000_R71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/art.40336","article-title":"Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2024110410421799000_R72","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1676-y","article-title":"A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira\u00ae) in the treatment of active rheumatoid arthritis","volume":"20","author":"Fleischmann","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2024110410421799000_R73","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1007\/s10067-019-04679-y","article-title":"Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis","volume":"38","author":"Edwards","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2024110410421799000_R74","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40259-020-00447-6","article-title":"Switching to biosimilar SDZ-ADL in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the phase III, randomized, double-blind ADMYRA study","volume":"34","author":"Wiland","year":"2020","journal-title":"BioDrugs"},{"key":"2024110410421799000_R75","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-2046-0","article-title":"FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, phase III, double-blind study, and its open-label extension","volume":"21","author":"Genovese","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024110410421799000_R76","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02394-7","article-title":"Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study","volume":"23","author":"Kay","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2024110410421799000_R77","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1371-4","article-title":"A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA\u00ae) to the reference product (Humira\u00ae) in patients with active rheumatoid arthritis","volume":"19","author":"Jamshidi","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2024110410421799000_R78","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/14712598.2019.1645114","article-title":"Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)","volume":"19","author":"Cohen","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"2024110410421799000_R79","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","article-title":"Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R80","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40259-020-00406-1","article-title":"Pharmacokinetic similarity and comparative pharmacodynamics, safety, efficacy, and immunogenicity of DRL_RI versus reference rituximab in biologics-na\u00efve patients with moderate-to-severe rheumatoid arthritis: a double-blind, randomized, three-arm study","volume":"34","author":"Haridas","year":"2020","journal-title":"BioDrugs"},{"key":"2024110410421799000_R81","article-title":"ClinicalTrials.gov: Study Details (NCT No. NCT02990806)","author":"National Library of Medicine"},{"key":"2024110410421799000_R82","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/rheumatology\/keaa234","article-title":"Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial","volume":"60","author":"Smolen","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024110410421799000_R83","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1080\/19420862.2018.1487912","article-title":"Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial","volume":"10","author":"Park","year":"2018","journal-title":"MAbs"},{"key":"2024110410421799000_R84","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40259-017-0232-7","article-title":"Efficacy, safety and pharmacokinetics of up to two courses of the rituximab biosimilar CT-P10 versus innovator rituximab in patients with rheumatoid arthritis: results up to week 72 of a phase I randomized controlled trial","volume":"31","author":"Yoo","year":"2017","journal-title":"BioDrugs"},{"key":"2024110410421799000_R85","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/cpdd.845","article-title":"A randomized, double-blind study comparing pharmacokinetics and pharmacodynamics of proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate to severe rheumatoid arthritis","volume":"9","author":"Burmester","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2024110410421799000_R86","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000876","article-title":"Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179\/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54","volume":"5","author":"Alten","year":"2019","journal-title":"RMD Open"},{"key":"2024110410421799000_R87","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2017-211741","article-title":"Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R88","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1907-x","article-title":"Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study","volume":"21","author":"Jaworski","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024110410421799000_R89","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/art.40444","article-title":"Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2024110410421799000_R90","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001578","article-title":"Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293","volume":"7","author":"Fleischmann","year":"2021","journal-title":"RMD Open"},{"key":"2024110410421799000_R91","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/rheumatology\/keab460","article-title":"Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg\/ml): 52-week randomized, double-blind study in rheumatoid arthritis","volume":"61","author":"Furst","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2024110410421799000_R92","first-page":"1025","article-title":"Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate: a 52-week phase III randomised study","volume":"40","author":"Matsuno","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2024110410421799000_R93","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/rheumatology\/kez152","article-title":"Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial","volume":"58","author":"Shim","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2024110410421799000_R94","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/acr.23771","article-title":"Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference rituximab in patients with active rheumatoid arthritis","volume":"71","author":"Tony","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024110410421799000_R95","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s10067-020-05305-y","article-title":"Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis","volume":"39","author":"Burmester","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2024110410421799000_R96","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/acr.23586","article-title":"Extension study of PF-05280586, a potential rituximab biosimilar, versus rituximab in subjects with active rheumatoid arthritis","volume":"70","author":"Cohen","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024110410421799000_R97","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.semarthrit.2015.11.004","article-title":"Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: a systematic review and meta-analysis","volume":"45","author":"Li","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2024110410421799000_R98","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2024110410421799000_R99","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/mr\/roac126","article-title":"Efficacy and safety of anti-TNF multivalent NANOBODY\u00ae compound \u2018ozoralizumab\u2019 without methotrexate co-administration in patients with active rheumatoid arthritis: a 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2024110410421799000_R100","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024110410421799000_R101","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024110410421799000_R102","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.140533","article-title":"Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population","volume":"42","author":"Hashimoto","year":"2015","journal-title":"J Rheumatol"},{"key":"2024110410421799000_R103","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3109\/14397595.2016.1141740","article-title":"Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: a nationwide cohort study in Japan","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2024110410421799000_R104","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/art.40017","article-title":"Rheumatoid arthritis and risk of malignant lymphoma: is the risk still increased?","volume":"69","author":"Hellgren","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024110410421799000_R105","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","article-title":"Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France","volume":"99","author":"Mariette","year":"2002","journal-title":"Blood"},{"key":"2024110410421799000_R106","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/14397595.2020.1869370","article-title":"Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: results from a Japanese multi-institutional retrospective study","volume":"32","author":"Honda","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024110410421799000_R107","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024110410421799000_R108","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae049\/58994308\/roae049.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/6\/1079\/60412201\/roae049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/6\/1079\/60412201\/roae049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T10:42:47Z","timestamp":1730716967000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/6\/1079\/7685364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":108,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,30]]},"published-print":{"date-parts":[[2024,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae049","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,5,30]]}}}